ThyroSeq Announces Results Of Large Multi-Center International Study Validating New ThyroSeq V3 Test To Be Presented At American Thyroid Association Annual Meeting

STUDY DEMONSTRATES HIGHLY ACCURATE PERFORMANCE OF THE TEST ALLOWING TO DECREASE LARGEST NUMBER OF AVOIDABLE DIAGNOSTIC THYROID SURGERIES

10/17/2017

NEW YORK, Oct. 9, 2017 /PRNewswire/ -- ThyroSeq®, a joint partnership between UPMC and CBLPath, announced today, that the results of a double-blind, multi-center international study, validating the performance of ThyroSeq V3® in thyroid nodules with indeterminate cytology, will be presented at the 87th Annual Meeting of the American Thyroid Association (ATA). The meeting will be held on October 18-22 in Victoria, BC, Canada. A clinical oral presentation and a poster presentation will demonstrate ThyroSeq's V3 effective tools for a definitive diagnosis and ability to decrease the largest number of avoidable diagnostic surgeries, thus providing the most cost-effective patient care.

"We are excited to have the opportunity to present our findings demonstrating the performance of this new, most comprehensive version of ThyroSeq for diagnosis of cancer in thyroid nodules," said Yuri Nikiforov, M.D., Ph.D, Professor of Pathology at University of Pittsburgh Medical Center, and principal investigator of the multi-center ThyroSeq V3 trial. "The results of rigorous test validation in multiple clinical centers in the U.S. and abroad provide confidence that this most accurate test will allow us to save the largest number of avoidable thyroid surgeries and offer individualized management of patients with thyroid nodules and cancer based on the cutting-edge genomic science."  

For more information and full story, visit
https://finance.yahoo.com/news/thyroseq-announces-results-large-multi-205600348.html